Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

计划入组 1,174 人 · 首次发布于 2017 年 1 月 30 日

Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer

计划入组 17 人 · 首次发布于 2006 年 2 月 1 日

Clinical Trial of the Safety and Tolerability of MMH-522 in Healthy Volunteers

计划入组 16 人 · 首次发布于 2026 年 8 月 10 日

GL-522

TXX-522

SYC-522

Reed-Lane, Inc.

United States

Lynk Biotechnologies Pte Ltd.

Singapore

University of Hohenheim

Germany

Pembrolizumab Plus Chemotherapy Improves Overall Survival in Early-Stage TNBC

Cleveland Clinic Reports Real-World Outcomes of KEYNOTE-522 Regimen in Triple-Negative Breast Cancer Treatment

Keytruda Demonstrates Significant Overall Survival Benefit in Early-Stage TNBC